Dear Colleagues

The human connectome at the level of fiber tracts between brain regions has been shown to differ in patients with brain disorders compared to healthy control groups. Nonetheless, there is a potentially large number of different network organizations for individual patients that could lead to cognitive deficits prohibiting correct diagnosis. Therefore, changes that can distinguish groups might not be sufficient to diagnose the disease that an individual patient suffers from and to indicate the best treatment option for that patient. We have to describe the challenges introduced by the large variability of connectomes within healthy subjects and patients and outline the common strategies to use connectomes as biomarkers of brain diseases. Finally, there may be an option in using models of simulated brain activity (the dynamic connectome) based on structural connectivity rather than the structure (connectome) itself as a biomarker of disease. Dynamic connectomes, in addition to currently used structural, functional, or effective connectivity, could be an important future biomarker for clinical applications.

For some drugs, measurement of expression of an obvious molecular drug target will provide a reasonably accurate basis for pharmacogenomic selection of patients

A pharmacogenomic profile can be used to identify patients who are either responsive to treatment or free of serious adverse events when treated.

In this conference we shall discuss what is new in these vital issues in the future of psychiatric practice.

Waiting for you to share and discuss with us and to enjoy our interesting scientific program.